SARS-CoV-2 Nucleoprotein 2 (326-340)
PSGTWLTYTGAIKLD is a SARS-CoV-2–specific T cell epitope from nucleoprotein 2 (326-340). It is an epitope that can be used for anti-viral targeting.
Catalogue number crb1001758 Molecular Weight 1621.8 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Jin et al., (2023). A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. Virus Research, 324, 199024. DOI: 10.1016/j.virusres.2022.199024.
Tarke et al., (2021). Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reps, 2(2): 100204. DOI: 10.1016/j.xcrm.2021.100204.
Manufactured in: United Kingdom
The coronavirus (CoV) nucleoprotein is the major component of CoV structural proteins. Also known as the nucleocapsid protein, it is an abundant RNA-binding protein critical for viral genome packaging. These factors make nucleoprotein a good target for developing new antiviral drugs. In addition, the identification of epitopes within the nucleoprotein sequence can help design more effective SARS-CoV-2 vaccines.
Models have predicted epitopes exhibiting antigenicity, stability and interactions with MHC class-I and class-II molecules. Nucleoprotein (261-275) is an epitope candidate with various HLA restrictions. This epitope can be used to better vaccine design for more durable CD4+ and CD8+ T cell responses for long-lasting immunity.